The US' new version of the proposed Biosecure Act would restrict federal agencies and contractors from using biotech equipment or services from entities, aimed at China, flagged as national security risks.

That may allow some of the contract manufacturing and development organisations (CDMO) in India to bag some of the business from the US.

These are the companies, like Divi’s Laboratories , which is the largest player in the space, that manufacture complex molecules, primary ingredients, on demand production of customised compounds, and other necessary inputs for the big pharma companies.

Currently, companies may not have the necessary strength to bag and execute the orders. "India must scale its workforce 6-7 times, streamline regulatory approvals, invest in R&D infrastructure, and

See Full Page